Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of aortic valve sclerosis with thrombin generation in hypertensive patients

Journal of Human Hypertension volume 22, pages 781–787 (2008)Cite this article

Abstract

Aortic valve sclerosis (AVS) may predispose to a prothrombotic state, as AVS is predictor of cardiovascular events in hypertensive populations. Thrombin exerts non-thrombotic effects such as vessel tone regulation, progression of atherosclerosis and stimulation of atrial natriuretic peptide (ANP) secretion. We hypothesized that hypertensive patients with AVS may have a persistently activated thrombin generation. We studied 234 asymptomatic never-treated hypertensive patients (73 of them with AVS). Prothrombin F1+2 (F1+2), as a marker of thrombin generation and fibrin D-dimer, as a marker of thrombus formation, ANP and brain natriuretic peptide (BNP) were measured. Presence of AVS, aortic jet velocity and left ventricular diameter at diastole were determined by echocardiography. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease formula. F1+2 (median and interquartile range (IQR)=1.05, 0.87–1.38 nM vs 0.93, 0.72–1.16) and ANP (22, 14–37 pg ml−1 vs 17, 11–25) levels were greater, and glomerular filtration rate values (65±9 ml min−1/1.73 m2 vs 68±11) were lower in hypertensive patients with AVS than in those without AVS. F1+2 (odds ratio, 95% CI=2.94, 1.07–8.6) was independently associated with AVS after being adjusted for age, gender and the variables of cardiorenal functions measured. After 6 months of treatment using valsartan, F1+2 levels remained elevated in hypertensive patients with AVS (1.14, 0.83–1.42 nM vs 1.07, 0.84–1.5, n=19), but decreased in those without AVS (1.01, 0.85–1.31 vs 0.8, 0.84–1.78, n=27). Thrombin generation was associated with AVS in untreated hypertensive patients, and this association was persistent after blood-pressure-lowering treatment using valsartan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Olsen MH, Wachtell K, Bella JN, Gerdts E, Palmieri V, Nieminen MS et al. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95: 132–136.

    Article  Google Scholar 

  2. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS . Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly [see comments]. N Engl J Med 1999; 341: 142–147.

    Article  CAS  Google Scholar 

  3. Freeman RV, Otto CM . Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316–3326.

    Article  Google Scholar 

  4. Merlini PA, Bauer KA, Mannucci PM . Laboratory detection of the prethrombotic state. In: Verstraete M, Fuster V, Topol J (eds). Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology, 2nd edn. Lippincott-Raven: Philadelphia, PA, 1998, pp 103–118.

    Google Scholar 

  5. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E . Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 2003; 41: 136–141.

    Article  Google Scholar 

  6. Lip GY . Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14: 687–690.

    Article  CAS  Google Scholar 

  7. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC . Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 41–53.

    Article  CAS  Google Scholar 

  8. Tracy RP . Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest 2003; 124: 49S–57S.

    Article  CAS  Google Scholar 

  9. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S . Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000; 36: 978–985.

    Article  CAS  Google Scholar 

  10. Jafri SM, Mammen EF, Masura J, Goldstein S . Effects of warfarin on markers of hypercoagulability in patients with heart failure. Am Heart J 1997; 134: 27–36.

    Article  CAS  Google Scholar 

  11. Klapper L, Nachshon S, Zamir O, Zamir N . Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium. J Pharmacol Exp Ther 1996; 278: 476–481.

    CAS  PubMed  Google Scholar 

  12. Curry FR . Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J Clin Invest 2005; 115: 1458–1461.

    Article  CAS  Google Scholar 

  13. Sechi LA, Zingaro L, Catena C, De Marchi S . Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events. Thromb Haemost 2000; 84: 565–570.

    Article  CAS  Google Scholar 

  14. Biasucci LM, Liuzzo G, Caligiuri G, Quaranta G, Andreotti F, Sperti G et al. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996; 93: 2121–2127.

    Article  CAS  Google Scholar 

  15. Nightingale AK, Horowitz JD . Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart 2005; 91: 1389–1393.

    Article  CAS  Google Scholar 

  16. Patterson C, Stouffer GA, Madamanchi N, Runge MS . New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987–997.

    Article  CAS  Google Scholar 

  17. Glembotski CC, Irons CE, Krown KA, Murray SF, Sprenkle AB, Sei CA . Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem 1993; 268: 20646–20652.

    CAS  PubMed  Google Scholar 

  18. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T . Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991; 87: 1999–2004.

    Article  CAS  Google Scholar 

  19. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400–405.

    Article  Google Scholar 

  20. Dielis AW, Smid M, Spronk HM, Hamulyak K, Kroon AA, ten Cate H et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005; 46: 1236–1242.

    Article  CAS  Google Scholar 

  21. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177: 155–160.

    Article  CAS  Google Scholar 

  22. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 2000; 157: 111–122.

    Article  CAS  Google Scholar 

  23. Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, Sanz-Rosa D, Ruilope LM et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens 2002; 20: 303–310.

    Article  CAS  Google Scholar 

  24. Ridker PM, Danielson E, Rifai N, Glynn RJ . Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 73–79.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Mitsubishi Nagoya Hospital, Nagoya, Aichi, Japan

    M Iida, M Yamamoto & M Yamazaki

  2. Department of Endocrinology, Shiga University of Medical Science, Shiga, Japan

    M Sawaguchi

  3. Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    H Honjo, I Kodama & K Kamiya

Authors
  1. M Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Sawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Honjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Iida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iida, M., Yamamoto, M., Yamazaki, M. et al. Association of aortic valve sclerosis with thrombin generation in hypertensive patients. J Hum Hypertens 22, 781–787 (2008). https://doi.org/10.1038/jhh.2008.68

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2008.68

Keywords

This article is cited by

Search

Advanced search

Quick links